I'll give them the benefit of the doubt till the August results, if they don't provide further light on them then I'd assume this to be the case. Institutional investors don't like companies that release what are deemed to be unnecessary updates as it can seem pumpy and a bit desperate (especially from companies with high risk of needing to raise capital - not applicable to Clinuvel obviously). Could simply be prudent investor relations, but there's absolutely no reason for them not to at least provide confirmation that they are on track and provide a specific timeline in the August results. It only takes looking at the share price for them to know they haven't been providing as much info as is needed for the market to value this properly. There's no competitive advantage associated with revealing specific timelines and confirming progress, every company does it whilst they're engaged in clinical trials.
Same for the cosmetic focused M lines... give us a product name and a release date at least if providing the specifics on how it actually works is too competitively sensitive. They need to confirm in clear terms that they have a product within the M lines prepared for launch in the near term, that's not at all commercially sensitive information but it's valuable info for shareholders.
- Forums
- ASX - By Stock
- CUV
- Ann: Ceasing to be a substantial holder
Ann: Ceasing to be a substantial holder, page-18
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CUV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.83 |
Change
-0.075(0.54%) |
Mkt cap ! $693.3M |
Open | High | Low | Value | Volume |
$14.00 | $14.00 | $13.71 | $959.2K | 69.31K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 189 | $13.81 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.84 | 110 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 275 | 13.800 |
1 | 38 | 13.760 |
1 | 38 | 13.750 |
1 | 38 | 13.740 |
1 | 35 | 13.730 |
Price($) | Vol. | No. |
---|---|---|
13.820 | 370 | 1 |
13.830 | 35 | 1 |
13.840 | 37 | 1 |
13.850 | 37 | 1 |
13.860 | 37 | 1 |
Last trade - 13.33pm 21/10/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online